Maternal and Fetal Resistin in Pre-gestational, Gestational and Non-Diabetic Pregnancies


  • Mary F. Higgins UCD Obstetrics and Gynaecology, School of Medicine and Medical Science, University College Dublin, National Maternity Hospital, Dublin, Ireland
  • Noirin M. Russell UCD Obstetrics and Gynaecology, School of Medicine and Medical Science, University College Dublin, National Maternity Hospital, Dublin, Ireland
  • Derek P. Brazil Center for Experimental Medicine, Queen’s University Belfast, Belfast, UK
  • Fionnuala M. McAuliffe UCD Obstetrics and Gynaecology, School of Medicine and Medical Science, University College Dublin, National Maternity Hospital, Dublin, Ireland



Resistin, diabetes, pregnancy.


Objective: To investigate possible differences in maternal and cord resistin between pregnancies affected by maternal gestational (GDM) and pre-gestational diabetes (PGDM) compared to non-diabetic pregnancies. Design: Prospective case control study. Setting: Tertiary level unit. Methods: Thirty-four women with PGDM (20 Type 1 diabetes and 14 Type 2 Diabetes) donated blood samples at 14, 20 and 36 weeks. Fourteen women with GDM donated blood samples at 36 weeks. Twelve control women in each trimester were matched on BMI to diabetic participants. Participants also consented for collection of matched cord samples after delivery. Resistin was measured by ELISA. Main Outcome Measures: Serum resistin, clinical measures (maternal age, parity, type of diabetes (non-diabetic, gestational diabetes, pre-gestational diabetes (type 1 diabetes (T1DM) or type 2 diabetes (T2DM)), maternal gylcaemia (HbA1c and fructosamine), gestation at delivery, method of delivery, and outcomes (birth weight, Apgars, cord pH, admission to neonatal intensive care (NICU), serum resistin concentration); comparison based on clinical group. Results: Maternal resistin was statistically significantly lower in T1DM compared to both non-diabetic and T2DM (maternal third trimester resistin in non-diabetic 37.5ng/ml (16-123), GDM 18.4 ng/ml (4.4-54.4), T2DM 40.5 ng/ml (5.7-109) and T1DM 3.7 ng/ml (1.7-10.6) (p<0.01); this difference held in cord samples. Conclusions: This is the first study investigating resistin in T1DM, T2DM and GDM maternal and cord blood. Despite the increase in insulin resistance with gestational diabetes and T2DM, there was no associated rise in maternal or cord resistin. The reduction in resistin in T1DM pregnancy may be protective as resistin also has a pro-inflammatory role.


Steppan, C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818): p. 307-12.

Le Lay, S., et al. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun 2001; 289(2): p. 564-7.

Higgins, M. and F. Mc Auliffe. A review of maternal and fetal growth factors in diabetic pregnancy. Curr Diabetes Rev 2010; 6(2): p. 116-25.

Ma, X., et al. Genetic variants at the resistin locus and risk of type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87(9): p. 4407-10.

Wang, H., et al. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87(6): p. 2520-4.

Sentinelli, F., et al. Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002; 51(3): p. 860-2.

Cho, Y.M., et al. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 2004; 47(3): p. 559-65.

Ryan, E.A. Hormones and insulin resistance during pregnancy. Lancet 2003; 362(9398): p. 1777-8.

Yura, S., et al. Resistin is expressed in the human placenta. J Clin Endocrinol Metab 2003; 88(3): p. 1394-7.

Cho, G.J., et al. Correlations between umbilical and maternal serum resistin levels and neonatal birth weight. Acta Obstet Gynecol Scand 2006; 85(9): p. 1051-6.

Chen, D., et al. Serum resistin in gestational diabetes mellitus and early postpartum. Clin Endocrinol (Oxf) 2007; 67(2): p. 208-11.

Kuzmicki, M., et al. High resistin and interleukin-6 levels are associated with gestational diabetes mellitus. Gynecol Endocrinol 2009; 25(4): p. 258-63.

Palik, E., et al. Elevated serum acylated (biologically active) ghrelin and resistin levels associate with pregnancy-induced weight gain and insulin resistance. Diabetes Res Clin Pract 2007; 76(3): p. 351-7.

Cortelazzi, D., et al. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol (Oxf) 2007; 66(3): p. 447-53.

Kulik-Rechberger, B. and O. Mora-Janiszewska. Serum resistin concentrations in cases of gestational diabetes mellitus with good glycemic control and in cord blood. Ginekol Pol 2009; 80(6): p. 432-6.

Nanda, S., et al. Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies. Metabolism 2012; 61(5): p. 699-705.

Megia, A., et al. Insulin sensitivity and resistin levels in gestational diabetes mellitus and after parturition. Eur J Endocrinol 2008; 158(2): p. 173-8.

Ng, P.C., et al. Plasma ghrelin and resistin concentrations are suppressed in infants of insulin-dependent diabetic mothers. J Clin Endocrinol Metab 2004; 89(11): p. 5563-8.

Griffin, M.E., et al. Universal vs. risk factor-based screening for gestational diabetes mellitus: detection rates, gestation at diagnosis and outcome. Diabet Med 2000; 17(1): p. 26-32.

Shojima, N., et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002; 51(6): p. 1737-44.

Heilbronn, L.K., et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004; 89(4): p. 1844-8.

Rajala, M.W., et al. Cell type-specific expression and coregulation of murine resistin and resistin-like moleculealpha in adipose tissue. Mol Endocrinol 2002; 16(8): p. 1920- 30.

Haugen, F., et al. Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 2001; 507(1): p. 105-8.

Kim, K.H., et al. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276(14): p. 11252-6.

Way, J.M., et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276(28): p. 25651-3.

Lappas, M., et al. Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol 2005; 186(3): p. 457-65.

Di Simone, N., et al. Resistin modulates glucose uptake and glucose transporter-1 (GLUT-1) expression in trophoblast cells. J Cell Mol Med 2009; 13(2): p. 388-97.

Kusminski, C.M., et al. The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J Clin Endocrinol Metab 2007; 92(1): p. 270-6.

Bokarewa, M., et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174(9): p. 5789- 95.

Kusanovic, J.P., et al. Resistin in amniotic fluid and its association with intra-amniotic infection and inflammation. J Matern Fetal Neonatal Med 2008; 21(12): p. 902-16.

Metzger, B.E., et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358(19): p. 1991-2002.